Identification

Name
Nadolol
Accession Number
DB01203  (APRD00301)
Type
Small Molecule
Groups
Approved
Description

A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for migraine disorders and for tremor. [PubChem]

Structure
Thumb
Synonyms
Not Available
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CorgardTablet20 mg/1OralUs World Meds, Llc2016-04-01Not applicableUs
CorgardTablet20 mg/1OralPfizer Laboratories Div Pfizer Inc.1979-12-10Not applicableUs
CorgardTablet40 mg/1OralUs World Meds, Llc2016-04-01Not applicableUs
CorgardTablet40 mg/1OralPfizer Laboratories Div Pfizer Inc.1979-12-10Not applicableUs
CorgardTablet80 mg/1OralUs World Meds, Llc2016-04-01Not applicableUs
CorgardTablet80 mg/1OralPfizer Laboratories Div Pfizer Inc.1979-12-10Not applicableUs
Corgard Tab 160mgTablet160 mgOralBristol Myers Squibb1981-12-312004-10-29Canada
Corgard Tab 40mgTablet40 mgOralBristol Myers Squibb1984-12-312006-05-29Canada
Corgard Tab 80mgTablet80 mgOralBristol Myers Squibb1979-12-312006-10-25Canada
NadololTablet80 mgOralAa Pharma Inc1988-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NadololTablet20 mg/1OralSandoz2008-10-01Not applicableUs
NadololTablet40 mg/1OralAmerincan Health Packaging2014-04-012015-12-31Us00781 1182 01 nlmimage10 a708d396
NadololTablet40 mg/1OralAmerincan Health Packaging2017-04-15Not applicableUs
NadololTablet20 mg/1OralCipla Limited2016-02-23Not applicableUs
NadololTablet80 mg/1OralCadila Pharnmaceuticals2017-08-08Not applicableUs
NadololTablet40 mg/1OralZydus Pharmaceuticals Usa, Inc.2017-08-08Not applicableUs
NadololTablet80 mg/1OralBlue Point Laboratories2016-02-23Not applicableUs
NadololTablet80 mg/1OralTeva2008-11-03Not applicableUs00093 4237 01 nlmimage10 2b2d958c
NadololTablet20 mg/1OralRebel Distributors2011-01-18Not applicableUs00093 4235 01 nlmimage10 222d910c
NadololTablet40 mg/1OralCadila Pharnmaceuticals2017-08-08Not applicableUs
International/Other Brands
Anabet / Corgard / Solgol
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
CorzideNadolol (80 mg/1) + Bendroflumethiazide (5 mg/1)TabletOralPfizer Laboratories Div Pfizer Inc.1983-05-25Not applicableUs
CorzideNadolol (40 mg/1) + Bendroflumethiazide (5 mg/1)TabletOralPfizer Laboratories Div Pfizer Inc.1983-05-25Not applicableUs
Corzide Tab W Nadolol 40mgNadolol (40 mg) + Bendroflumethiazide (5 mg)TabletOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1987-12-311997-08-14Canada
Corzide Tab W Nadolol 80mgNadolol (80 mg) + Bendroflumethiazide (5 mg)TabletOralSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.1987-12-311997-08-14Canada
Nadolol and BendroflumethiazideNadolol (40 mg/1) + Bendroflumethiazide (5 mg/1)TabletOralImpax Generics2007-03-30Not applicableUs
Nadolol and BendroflumethiazideNadolol (80 mg/1) + Bendroflumethiazide (5 mg/1)TabletOralImpax Generics2007-03-30Not applicableUs
Categories
UNII
FEN504330V
CAS number
42200-33-9
Weight
Average: 309.4006
Monoisotopic: 309.194008357
Chemical Formula
C17H27NO4
InChI Key
VWPOSFSPZNDTMJ-UCWKZMIHSA-N
InChI
InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1
IUPAC Name
(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol
SMILES
CC(C)(C)NCC(O)COC1=CC=CC2=C1C[[email protected]](O)[[email protected]](O)C2

Pharmacology

Indication

Used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension.

Structured Indications
Pharmacodynamics

Nadolol is a nonselective beta-adrenergic receptor antagonist with a long half-life, and is structurally similar to propranolol. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood pressure at rest and on exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. Nadolol has no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, nadolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.

Mechanism of action

Like other beta-adrenergic antagonists, nadolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, nadolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, nadolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Nadolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
UBeta-2 adrenergic receptor
antagonist
Human
Absorption

Absorption of nadolol after oral dosing is variable, averaging about 30 percent.

Volume of distribution
Not Available
Protein binding

30%

Metabolism

Not metabolized by the liver and excreted unchanged primarily by the kidneys.

Route of elimination

Unlike many other beta-adrenergic blocking agents, nadolol is not metabolized by the liver and is excreted unchanged, principally by the kidneys. Nadolol is excreted predominantly in the urine.

Half life

14-24 hours

Clearance
Not Available
Toxicity

Oral, mouse: LD50 = 4500mg/kg. Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Nadolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Nadolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Nadolol.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nadolol.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nadolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Nadolol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Nadolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Nadolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Nadolol.Approved
AcetohexamideNadolol may increase the hypoglycemic activities of Acetohexamide.Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Nadolol is combined with Acetylcholine.Approved
AcetyldigitoxinNadolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinNadolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Nadolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Nadolol.Experimental, Investigational
AlaproclateThe serum concentration of Nadolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Nadolol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nadolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Nadolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Nadolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Nadolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Nadolol is combined with Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Nadolol.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Nadolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Nadolol.Approved
AmbrisentanNadolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineNadolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nadolol.Approved
AmiodaroneAmiodarone may increase the bradycardic activities of Nadolol.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nadolol.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Nadolol.Approved, Illicit
AmodiaquineThe metabolism of Nadolol can be decreased when combined with Amodiaquine.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Nadolol.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nadolol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Nadolol is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Nadolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Nadolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Nadolol.Approved
ApocyninApocynin may decrease the antihypertensive activities of Nadolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Nadolol.Approved
ApremilastApremilast may decrease the antihypertensive activities of Nadolol.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Nadolol is combined with Arecoline.Experimental
AripiprazoleAripiprazole may increase the hypotensive activities of Nadolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nadolol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nadolol.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Nadolol.Approved
AvanafilAvanafil may increase the antihypertensive activities of Nadolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Nadolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Nadolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nadolol is combined with Azilsartan medoxomil.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Nadolol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Nadolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Nadolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Nadolol.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nadolol.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Nadolol.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nadolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nadolol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Nadolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Nadolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Nadolol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Nadolol.Approved, Withdrawn
BeractantNadolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nadolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Nadolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Nadolol.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Nadolol.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Nadolol.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nadolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Nadolol.Investigational
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Nadolol.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Nadolol.Approved, Investigational
BQ-123Nadolol may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the bradycardic activities of Nadolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Nadolol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Nadolol.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Nadolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Nadolol.Investigational
BucindololNadolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Nadolol.Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Nadolol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nadolol.Approved
BunazosinNadolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Nadolol.Approved, Investigational
BupranololNadolol may increase the hypotensive activities of Bupranolol.Approved
CabergolineNadolol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Nadolol.Experimental
CafedrineNadolol may increase the hypotensive activities of Cafedrine.Investigational
CalfactantNadolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Nadolol is combined with Canagliflozin.Approved
CandesartanNadolol may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nadolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Nadolol.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Nadolol.Approved
CarbacholThe risk or severity of adverse effects can be increased when Nadolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Nadolol.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nadolol.Approved
CarbutamideNadolol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Nadolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Nadolol.Approved
CarvedilolNadolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Nadolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Nadolol.Approved, Investigational
CeliprololNadolol may increase the hypotensive activities of Celiprolol.Approved, Investigational
CeritinibNadolol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Nadolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Nadolol can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nadolol.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Nadolol.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Nadolol.Approved, Vet Approved
ChlorpropamideNadolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nadolol.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Nadolol.Approved
CicletanineNadolol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Nadolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nadolol.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Nadolol is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Nadolol.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nadolol.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Nadolol.Approved
CloranololNadolol may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Nadolol.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Nadolol.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Nadolol.Vet Approved
CrizotinibNadolol may increase the bradycardic activities of Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Nadolol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Nadolol.Investigational
CyclopenthiazideNadolol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Nadolol.Approved
CymarinNadolol may increase the bradycardic activities of Cymarin.Experimental
D-LimoneneD-Limonene may decrease the antihypertensive activities of Nadolol.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Nadolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Nadolol can be increased when it is combined with Dapoxetine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Nadolol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Nadolol.Approved
DelaprilNadolol may increase the hypotensive activities of Delapril.Experimental
DemecariumDemecarium may increase the bradycardic activities of Nadolol.Approved
DeserpidineNadolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nadolol.Approved
DeslanosideNadolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Nadolol can be increased when it is combined with Desvenlafaxine.Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Nadolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Nadolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Nadolol.Approved
diethylnorspermineNadolol may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Nadolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Nadolol.Approved
DigitoxinNadolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinDigoxin may increase the bradycardic activities of Nadolol.Approved
Digoxin Immune Fab (Ovine)Nadolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Nadolol.Investigational
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Nadolol.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Nadolol is combined with Dinutuximab.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Nadolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Nadolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Nadolol.Experimental
DonepezilDonepezil may increase the bradycardic activities of Nadolol.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Nadolol.Approved
DoxazosinNadolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DronedaroneDronedarone may increase the bradycardic activities of Nadolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Nadolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Investigational
DuloxetineNadolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Nadolol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Nadolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Nadolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Nadolol.Approved
EfonidipineNadolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Nadolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nadolol.Approved, Vet Approved
EnalaprilatNadolol may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Nadolol.Experimental
EpanololNadolol may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Nadolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Nadolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nadolol.Approved
EpoprostenolNadolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nadolol.Approved
Ergoloid mesylateNadolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineNadolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nadolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nadolol.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Nadolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Nadolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Nadolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Nadolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
EtoperidoneThe serum concentration of Nadolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Nadolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Nadolol.Approved, Investigational
exisulindexisulind may decrease the antihypertensive activities of Nadolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Nadolol.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Nadolol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Nadolol.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Nadolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Nadolol.Approved
FentanylFentanyl may increase the bradycardic activities of Nadolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Nadolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Nadolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Nadolol.Experimental
Ferulic acidNadolol may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nadolol.Approved, Investigational
FingolimodNadolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Nadolol.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Nadolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Nadolol.Experimental
FluoxetineThe serum concentration of Nadolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Nadolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Nadolol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nadolol.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Nadolol.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nadolol.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Nadolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Nadolol.Approved
GitoformateNadolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideNadolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideNadolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideNadolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideNadolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneNadolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideNadolol may increase the hypoglycemic activities of Glisoxepide.Approved, Investigational
GlyburideNadolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Nadolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Nadolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Nadolol.Approved
GuanazodineNadolol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Nadolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Investigational
GuanoclorNadolol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzNadolol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanNadolol may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Nadolol.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Nadolol.Experimental
HexamethoniumNadolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Nadolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Nadolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Nadolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Nadolol.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Nadolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nadolol.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Nadolol.Approved, Investigational
HydroxychloroquineThe metabolism of Nadolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Nadolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Nadolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Nadolol.Approved
IloprostIloprost may increase the hypotensive activities of Nadolol.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Nadolol.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Nadolol.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Nadolol.Approved
IndalpineThe serum concentration of Nadolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Nadolol.Approved
IndenololNadolol may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenIndobufen may decrease the antihypertensive activities of Nadolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Nadolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Nadolol.Withdrawn
IndoraminNadolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanNadolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkNadolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Nadolol.Experimental
IproclozideIproclozide may increase the hypotensive activities of Nadolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Nadolol.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nadolol.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nadolol.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nadolol.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Nadolol.Approved, Investigational, Withdrawn
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nadolol.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nadolol.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Nadolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Nadolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Nadolol.Approved
IvabradineNadolol may increase the bradycardic activities of Ivabradine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Nadolol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Nadolol.Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Nadolol.Approved
LabetalolNadolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineNadolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideNadolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
Lanatoside CNadolol may increase the bradycardic activities of Lanatoside C.Experimental
LanreotideNadolol may increase the bradycardic activities of Lanreotide.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Nadolol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Nadolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Nadolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Nadolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nadolol.Approved, Investigational
LevodopaNadolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Nadolol can be increased when it is combined with Levomilnacipran.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Nadolol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Nadolol.Approved, Vet Approved
LinsidomineNadolol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nadolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Nadolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Nadolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Nadolol.Experimental
LornoxicamLornoxicam may decrease the antihypertensive activities of Nadolol.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nadolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Nadolol.Approved, Investigational
LucinactantNadolol may increase the bradycardic activities of Lucinactant.Approved, Investigational
LumacaftorThe serum concentration of Nadolol can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Nadolol.Approved, Investigational
MacitentanNadolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Nadolol.Approved
MalathionMalathion may increase the bradycardic activities of Nadolol.Approved, Investigational
ManidipineNadolol may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Nadolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Nadolol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Nadolol.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Nadolol.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Nadolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Nadolol.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Nadolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Nadolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Nadolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Nadolol.Approved, Investigational
MetahexamideNadolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Nadolol.Investigational, Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Nadolol is combined with Methacholine.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Nadolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Nadolol.Approved
MethohexitalMethohexital may increase the hypotensive activities of Nadolol.Approved
MethoserpidineNadolol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Nadolol.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nadolol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Nadolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nadolol.Approved, Investigational
MethylergometrineNadolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nadolol.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nadolol.Approved
MetildigoxinNadolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Nadolol is combined with Metipranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Nadolol.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Nadolol.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nadolol.Approved, Investigational
MetyrosineNadolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilNadolol may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineNadolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Nadolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Nadolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nadolol.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Nadolol.Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Nadolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Nadolol.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Nadolol.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Nadolol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Nadolol.Approved, Investigational
MoricizineMoricizine may increase the hypotensive activities of Nadolol.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nadolol.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Investigational
MuzolimineNadolol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Nadolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Nadolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Nadolol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Nadolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Nadolol.Approved
NaftopidilNadolol may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Nadolol is combined with Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nadolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Nadolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Nadolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nadolol is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Nadolol.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nadolol.Approved
NicorandilNicorandil may increase the hypotensive activities of Nadolol.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Nadolol is combined with Nicotine.Approved
NifedipineNifedipine may increase the hypotensive activities of Nadolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Nadolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Nadolol.Approved
NiguldipineNadolol may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineNadolol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Nadolol.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nadolol.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nadolol.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Nadolol.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Nadolol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Nadolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nadolol.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Nadolol.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
ObinutuzumabNadolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Nadolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Nadolol.Approved, Investigational
OleandrinNadolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nadolol.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Nadolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Nadolol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Nadolol.Investigational
OrgoteinOrgotein may decrease the antihypertensive activities of Nadolol.Vet Approved
OuabainNadolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Nadolol.Approved
OxprenololNadolol may increase the hypotensive activities of Oxprenolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Nadolol.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nadolol.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Nadolol.Approved
ParaoxonParaoxon may increase the bradycardic activities of Nadolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Nadolol.Approved
PargylinePargyline may increase the hypotensive activities of Nadolol.Approved
ParoxetineThe serum concentration of Nadolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Nadolol.Investigational
PasireotideNadolol may increase the bradycardic activities of Pasireotide.Approved
PenbutololThe risk or severity of adverse effects can be increased when Nadolol is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Nadolol.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Nadolol.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nadolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Nadolol.Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Nadolol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Nadolol.Approved
PeruvosideNadolol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Nadolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Nadolol.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Nadolol.Approved
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Nadolol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nadolol.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Nadolol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Nadolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Nadolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Nadolol.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Nadolol.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Nadolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nadolol.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Nadolol.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Nadolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Nadolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Nadolol.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Nadolol.Withdrawn
Platelet Activating FactorNadolol may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideNadolol may increase the hypotensive activities of Polythiazide.Approved
Poractant alfaNadolol may increase the bradycardic activities of Poractant alfa.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nadolol.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Nadolol.Experimental, Investigational
PrazosinNadolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Nadolol can be decreased when combined with Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Nadolol.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Nadolol.Approved
ProchlorperazineProchlorperazine may increase the hypotensive activities of Nadolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Nadolol.Experimental
PromazinePromazine may increase the hypotensive activities of Nadolol.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Nadolol.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Nadolol.Approved, Investigational
PropafenoneThe serum concentration of Nadolol can be increased when it is combined with Propafenone.Approved
PropericiazinePropericiazine may increase the hypotensive activities of Nadolol.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Nadolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Nadolol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Nadolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Nadolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Nadolol.Experimental
ProscillaridinNadolol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Nadolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Nadolol.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Nadolol is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Nadolol.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Nadolol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nadolol.Approved
RanolazineThe serum concentration of Nadolol can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Nadolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Nadolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nadolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Nadolol.Approved
RescinnamineNadolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Nadolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Nadolol.Approved, Experimental, Investigational
RifampicinThe serum concentration of Nadolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Nadolol can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Nadolol can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Nadolol.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Nadolol is combined with Riociguat.Approved
RisperidoneNadolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabNadolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineRivastigmine may increase the bradycardic activities of Nadolol.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Nadolol.Investigational, Withdrawn
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nadolol.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Nadolol.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Nadolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Nadolol.Approved
SafrazineSafrazine may increase the hypotensive activities of Nadolol.Withdrawn
SalicylamideSalicylamide may decrease the antihypertensive activities of Nadolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved
SalsalateSalsalate may decrease the antihypertensive activities of Nadolol.Approved
SaprisartanNadolol may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Nadolol.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Nadolol.Approved, Investigational, Vet Approved
SelexipagNadolol may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Nadolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Nadolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Nadolol.Investigational
SertralineThe serum concentration of Nadolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nadolol.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Nadolol.Approved, Investigational
SilodosinNadolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SitaxentanNadolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Nadolol.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Nadolol.Approved
SpiraprilNadolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nadolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Nadolol.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Nadolol.Approved, Investigational
SufentanilSufentanil may increase the bradycardic activities of Nadolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Nadolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Nadolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Nadolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Nadolol.Experimental
TacrineTacrine may increase the bradycardic activities of Nadolol.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Nadolol.Approved, Investigational
TalinololNadolol may increase the hypotensive activities of Talinolol.Investigational
TamsulosinNadolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Nadolol.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nadolol.Approved, Investigational
TemocaprilNadolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Nadolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Nadolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Nadolol.Vet Approved
TerazosinNadolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Nadolol.Approved
TerlipressinNadolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrahydropalmatineNadolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nadolol.Approved, Investigational, Withdrawn
TheodrenalineNadolol may increase the hypotensive activities of Theodrenaline.Investigational
ThiamylalThiamylal may increase the hypotensive activities of Nadolol.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Nadolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Nadolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Nadolol.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Nadolol.Approved
ThioridazineThioridazine may increase the hypotensive activities of Nadolol.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Nadolol.Approved
TiboloneNadolol may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenNadolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Nadolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Nadolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Nadolol.Approved, Investigational
TolazamideNadolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineTolazoline may increase the hypotensive activities of Nadolol.Approved, Vet Approved
TolbutamideNadolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nadolol.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Nadolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Nadolol.Approved
TolonidineNadolol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Nadolol.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nadolol.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nadolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Nadolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nadolol.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Nadolol.Approved
TravoprostTravoprost may increase the hypotensive activities of Nadolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Nadolol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Nadolol.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nadolol.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Nadolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Nadolol.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Nadolol.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Nadolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Nadolol.Approved, Vet Approved
TrimazosinNadolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Nadolol.Approved, Investigational
TriptolideTriptolide may decrease the antihypertensive activities of Nadolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Nadolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Nadolol.Approved, Investigational
UnoprostoneNadolol may increase the hypotensive activities of Unoprostone.Approved
UrapidilNadolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Nadolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nadolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Nadolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Nadolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Nadolol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Nadolol.Approved
VincamineNadolol may increase the hypotensive activities of Vincamine.Experimental
VinpocetineNadolol may increase the hypotensive activities of Vinpocetine.Investigational
XipamideNadolol may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Nadolol.Approved, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Nadolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Nadolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Nadolol can be increased when it is combined with Zimelidine.Withdrawn
ZofenoprilNadolol may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Nadolol.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Magnesium, potassium and zinc needs increased.
  • Take without regard to meals.

References

Synthesis Reference
US3935267
General References
Not Available
External Links
Human Metabolome Database
HMDB15334
KEGG Drug
D00432
PubChem Compound
39147
PubChem Substance
46505509
ChemSpider
35815
BindingDB
25766
ChEBI
7444
ChEMBL
CHEMBL649
Therapeutic Targets Database
DAP000122
PharmGKB
PA450573
IUPHAR
554
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Nadolol
ATC Codes
C07AA12 — NadololC07BA12 — Nadolol and thiazides
AHFS Codes
  • 24:24.00 — Beta-adrenergic Blocking Agents
MSDS
Download (74.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
1, 2CompletedTreatmentAsthma Bronchial1
2Active Not RecruitingTreatmentMild Persistent Asthma, Uncomplicated1
2CompletedTreatmentCessation, Smoking1
2CompletedTreatmentInfantile Hemangiomas1
3RecruitingTreatmentInfantile Hemangiomas1
3WithdrawnPreventionHemorrhage, Gastrointestinal / Portal Hypertension1
4CompletedPreventionHemorrhage, Gastrointestinal / Liver Cirrhosis / Portal Hypertension1
4CompletedPreventionLiver Cirrhosis / Variceal Bleeding1
4CompletedPreventionVariceal Rebleeding1
4CompletedTreatmentMigrainous Headache1
4Unknown StatusPreventionGastric Variceal Bleeding / Liver Cirrhosis and Hepatoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral
TabletOral160 mg
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral80 mg/1
TabletOral40 mg
TabletOral80 mg
Prices
Unit descriptionCostUnit
Nadolol powder94.8USD g
Corgard 160 mg tablet4.4USD tablet
Corgard 80 mg tablet4.33USD tablet
Corgard 120 mg tablet3.96USD tablet
Corgard 40 mg tablet3.11USD tablet
Corgard 20 mg tablet3.04USD tablet
Nadolol 160 mg tablet2.25USD tablet
Nadolol 80 mg tablet1.45USD tablet
Apo-Nadol 160 mg Tablet1.26USD tablet
Nadolol 40 mg tablet1.07USD tablet
Naldol 80 mg tablet1.03USD tablet
Nadolol 20 mg tablet0.92USD tablet
Apo-Nadol 80 mg Tablet0.37USD tablet
Novo-Nadolol 80 mg Tablet0.37USD tablet
Apo-Nadol 40 mg Tablet0.26USD tablet
Novo-Nadolol 40 mg Tablet0.26USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)124-136 °CPhysProp
water solubility8330 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP0.81SANGSTER (1994)
Caco2 permeability-5.41ADME Research, USCD
pKa9.67MERCK INDEX (2001)
Predicted Properties
PropertyValueSource
Water Solubility2.25 mg/mLALOGPS
logP1.23ALOGPS
logP0.87ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)13.59ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area81.95 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity85.53 m3·mol-1ChemAxon
Polarizability34.63 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9788
Blood Brain Barrier-0.966
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8317
P-glycoprotein inhibitor IInhibitor0.6192
P-glycoprotein inhibitor IINon-inhibitor0.7842
Renal organic cation transporterNon-inhibitor0.8736
CYP450 2C9 substrateNon-substrate0.7934
CYP450 2D6 substrateSubstrate0.7284
CYP450 3A4 substrateNon-substrate0.5456
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8072
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8934
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.7972 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9455
hERG inhibition (predictor II)Inhibitor0.5781
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-03di-0019000000-fdb4087c676d8d8d4a8e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0092000000-e09452da687c6073a284
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0uk9-4690000000-81baaf08e07647128956
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0kmi-4930000000-adbaba8c066f6c5c5558
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0aba-3900000000-3784678375e682bb5b2f
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05te-3900000000-52bc796915dc7eb2ff30
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0ik9-0379000000-d94563052914b6b9e468
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0k92-2920000000-2a6eb574de4bc8d52292

Taxonomy

Description
This compound belongs to the class of organic compounds known as tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Tetralins
Sub Class
Not Available
Direct Parent
Tetralins
Alternative Parents
Alkyl aryl ethers / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Tetralin / Alkyl aryl ether / 1,2-aminoalcohol / Secondary alcohol / Secondary aliphatic amine / Ether / Secondary amine / Organic nitrogen compound / Organooxygen compound / Organonitrogen compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Wheeldon NM, McDevitt DG, Lipworth BJ: The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2-adrenoceptor blockade. Br J Clin Pharmacol. 1994 Aug;38(2):103-8. [PubMed:7981009]
  3. Koshiji M, Ito H, Minatoguchi S, Watanabe H, Imai Y, Kakami M, Hirakawa S: A comparison of guanfacine, bunazosin, atenolol and nadolol on blood pressure and plasma noradrenaline responses to cold pressor testing. Clin Exp Pharmacol Physiol. 1992 Jul;19(7):481-8. [PubMed:1354084]
  4. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496]
  5. Varma DR: Ligand-independent negative chronotropic responses of rat and mouse right atria to beta-adrenoceptor antagonists. Can J Physiol Pharmacol. 1999 Dec;77(12):943-9. [PubMed:10606440]
  6. Wheeldon NM, McDevitt DG, Lipworth BJ: Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man. Br J Clin Pharmacol. 1994 Apr;37(4):363-9. [PubMed:7912539]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Wheeldon NM, McDevitt DG, Lipworth BJ: The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2-adrenoceptor blockade. Br J Clin Pharmacol. 1994 Aug;38(2):103-8. [PubMed:7981009]
  3. Ozakca I, Arioglu E, Guner S, Altan VM, Ozcelikay AT: Role of beta-3-adrenoceptor in catecholamine-induced relaxations in gastric fundus from control and diabetic rats. Pharmacology. 2007;80(4):227-38. Epub 2007 Jul 6. [PubMed:17622774]
  4. Liu YL, Toubro S, Astrup A, Stock MJ: Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int J Obes Relat Metab Disord. 1995 Sep;19(9):678-85. [PubMed:8574280]
  5. Wheeldon NM, McDevitt DG, Lipworth BJ: Evaluation of in vivo partial beta 1/beta 2-agonist activity: a dose-ranging study with carteolol. Br J Clin Pharmacol. 1992 Apr;33(4):411-6. [PubMed:1349493]
  6. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A: Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol. 1996 Oct;48(10):1083-9. [PubMed:8953513]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34